Want to join the conversation?
$REGN said in full-year 2016 it expects EYLEA US net product sales to be up 20-25% over 2015. Sanofi reimbursement of Regeneron commercialization-related expenses are expected to be $320-370MM in 2016. CapEx is expected to be in the range of $550-625MM, down from the previous range of $580-680MM.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.